THOMAS WHEELER to Combined Modality Therapy
This is a "connection" page, showing publications THOMAS WHEELER has written about Combined Modality Therapy.
Connection Strength
0.158
-
Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer. Am J Surg Pathol. 2001 Nov; 25(11):1429-32.
Score: 0.035
-
Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia. Eur Urol. 1996; 30(2):261-4.
Score: 0.024
-
Outcomes of combination treatment of fecal incontinence in women. Am J Obstet Gynecol. 2008 Dec; 199(6):699.e1-7.
Score: 0.014
-
Malignant advanced granulosa cell tumor of the adult testis: case report and review of the literature. Hum Pathol. 2008 May; 39(5):701-9.
Score: 0.014
-
Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat. 2006 Feb; 5(1):23-36.
Score: 0.012
-
Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):562-71.
Score: 0.011
-
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
Score: 0.010
-
IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):184-91.
Score: 0.010
-
Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist. 2002; 7(5):458-66.
Score: 0.009
-
Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):605-13.
Score: 0.009
-
In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther. 1999 May 01; 10(7):1239-49.
Score: 0.007
-
Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J Urol. 1988 Sep; 140(3):544-9.
Score: 0.004